1999
DOI: 10.1590/s0004-27301999000500005
|View full text |Cite
|
Sign up to set email alerts
|

Monitorizando a terapia de reposição estrogênica (TRE) na menopausa

Abstract: RESUMOAcompanhamos 62 mulheres pós-menopausadas, previamente sintomáticas, mensalmente, durante 3 meses após início de terapia de reposição estrogênica (TRE) com 17-beta estradiol em gel percutâ-neo, na dose de 0,75 a 3,0 mg/dia (meia a duas réguas). Nas com útero, associou-se progesterone natural micronizada, 100 a 200 mg/dia cíclica ou contínua, ou acetato de medroxiprogesterona, 5 mg/dia cíclico. Durante tratamento, todas as pacientes com fogachos ou secura vaginal apresentaram níveis de E2 sérico <53 pg/ml… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
1
0
2

Year Published

2000
2000
2016
2016

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 25 publications
2
1
0
2
Order By: Relevance
“…Weight did not change in the three groups during follow-up. The same variation in waist circumference was demonstrated by our group in postmenopausal women, at the beginning of hormone replacement therapy (35). With regard to waist-to-hip ratio, some studies have shown that testosterone replacement rapidly improved this ratio, particularly when associated with regular physical exercise (36), thus representing an important parameter for metabolic syndrome improvement.…”
Section: Discussionsupporting
confidence: 79%
“…Weight did not change in the three groups during follow-up. The same variation in waist circumference was demonstrated by our group in postmenopausal women, at the beginning of hormone replacement therapy (35). With regard to waist-to-hip ratio, some studies have shown that testosterone replacement rapidly improved this ratio, particularly when associated with regular physical exercise (36), thus representing an important parameter for metabolic syndrome improvement.…”
Section: Discussionsupporting
confidence: 79%
“…Growth hormone therapy is associated with some collateral effects, including edema and is also correlated to insulin resistance, which can deteriorate endothelial function. 30 The same effect is reported with use of estrogens 31 and the high prevalence found in this study may be explained by this collateral effect. On the other hand, estrogen receptors are present in vascular smooth muscle and endothelial cells and the use of estrogen therapy has a favorable effect on cardiovascular hemodynamics in TS.…”
Section: Discussionsupporting
confidence: 69%
“…During the interval between NVC, the participant was asked about color, TSM, timing and duration of HT, previous oral contraceptive (OC) use, past smoking, and current vasomotor symptoms, quantified subjectively from 0 (no symptoms) to 10 (very intense symptoms). 19 BP was determined from two measurements at least 2 minutes apart. Height, weight, waist circumference (halfway between the costal margin and the iliac crest on the midclavicle line), and body mass index (BMI, in kilograms per square meter) were assessed.…”
Section: Methodsmentioning
confidence: 99%